Antibody response to SARS-CoV-2 vaccines among hospitalized patients in China: a case-control study. Issue 5 (30th November 2022)

• Record Type: Journal Article
• Authors: Li, Fei-Ping; Shi, Gui-Feng; Lin, Zhen-Zhen; Zhu, Xiao-Liang; Wang, Li-Jun; Tung, Tao-Hsin; Zhang, Mei-Xian
• Is Part Of: Human vaccines & immunotherapeutics. Volume 18:Issue 5(2022)
• Publication Date: 2022-11-30
• Subjects: SARS-CoV-2 vaccine -- antibody response -- hospitalization -- case-control study -- China; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2022.2088966
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: A lack of confidence on the vaccination drive hinders the management of the COVID-19 pandemic. We aimed to assess the antibody response to the SARS-CoV-2 vaccine among hospitalized patients in China. This case-control study was based on SARS-CoV-2 sero-surveillance during hospitalization. From April to June 2021, hospitalized patients without documented COVID-19 infection from the Department of Urology were routinely assayed for anti-SARS-CoV-2 antibodies. The SARS-CoV-2 vaccination history of each participant was obtained from their vaccination records. Of the 405 participants, there were 37 seropositive participants (case group) and 368 seronegative participants (control group); 68 participants (16.8%) had received the inactivated SARS-CoV-2 vaccine, including 54 who received the Sinovac-CoronaVac vaccine and 14 received the Sinopharm vaccine. All seropositive participants who had received one or two doses of the SARS-CoV-2 vaccine were assessed for at least 16 days, while 31 (8.4%) of 368 seronegative controls who had received the vaccine were tested for 1–94 days. The overall seroconversion rate was 54.4% (37/68) in the vaccinated participants who received the inactivated SARS-CoV-2 vaccine. The odds ratio (OR) and confidence interval (CI) for seropositivity was 6.20 (95% CI: 2.05–18.71) in those received full vaccination with two doses versus those partially vaccinated participants with one dose after adjusting for sex and age. These findings imply that the inactivated SARS-CoV-2 vaccine could have a protective antibody response.